Compare Ecolab Inc. (ECL) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecolab Inc. vs BIO-TECHNE Corp — how do they compare? Ecolab Inc. trades at $281.36 (market cap $78.97B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: Ecolab Inc. is far larger — about 7× BIO-TECHNE Corp's market cap, and Ecolab Inc. pays the higher dividend (1.04%). Which is the better fit depends on your goals — on Pluang, investors hold Ecolab Inc. for 90 Days and BIO-TECHNE Corp for 63 Days on average.
| ECL | TECH | |
|---|---|---|
Market Cap | $78.97B | $11.36B |
Volume | 974,947 | 5,390,331 |
Sector | Basic Materials | Health |
52-Week High | $308.35 | $72.61 |
52-Week Low | $245.73 | $43.31 |
Typical Hold Time | 90 Days | 63 Days |
Enterprise Value | $87.75B | $11.39B |
Dividend Yield | 1.04% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ECL trades at $278.10, down 0.97% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported $16.08B in 2025 revenue, with a net income margin of 12.57% and strong profitability metrics. Recent news highlights its dividend aristocrat status and growth in high-tech segments, while institutional buying and insider purchases reflect confidence.
Outlook remains positive with a consensus price target of $326.38, implying 17% upside, supported by analyst buy ratings (78%). Risks include elevated valuation multiples and increased debt from the CoolIT acquisition. Earnings growth in high-tech and digital segments is a key catalyst, though cost fluctuations pose headwinds.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
